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Abstract 
Osteoporosis is a multifactorial disease with a strong genetic component characterised 
by reduced bone density and increased fracture risk.  A candidate locus for regulation 
of hip bone mineral density (BMD) has been identified on chromosome 1p36 by 
linkage analysis.  One of the positional and functional candidate genes located within 
this region is the tumour necrosis factor receptor superfamily member 1B 
(TNFRSF1B).  In order to investigate whether allelic variation in TNFRSF1B 
contributes to regulation of bone mass, we studied several polymorphisms of this gene 
in a population based cohort study of 1240 perimenopausal women from the UK.  We 
studied a T676G change in exon 6 (196:Met-Arg) and three SNPs (G593A, T598G, 
and T620C) in the 3’UTR of the gene.  The 3’UTR SNPs were in strong linkage 
disequilibrium (LD) with each other (p<0.00001), and the exon 6 SNP was in LD with 
G593A and T598G (p<0.00001).  We found no association between T676G alleles 
and BMD at the spine or hip.  However, haplotype analysis showed that subjects 
homozygous for the A593-T598-C620 haplotype (n=85) had femoral neck BMD 
values 5.7% lower than those who did not carry the haplotype (n=1155; p<0.00008) 
and this remained significant after correcting for confounding factors and multiple 
testing (p<0.0009).  Regression analysis showed that the ATC haplotype accounted 
for 1.2% of the population variance in hip BMD and was the second strongest 
predictor after body weight.  In summary, our work supports the view that allelic 
variation in the 3’UTR of TNFRSF1B gene contributes to the genetic regulation of 
bone mass, with effects that are specific for femoral neck BMD.  
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Introduction. 
Osteoporosis is a common disease with a strong genetic component characterised by 
low bone mineral density (BMD), microarchitectural deterioration of bone tissue and 
an increased risk of fracture after minimal trauma (1).  Twin and family studies have 
shown that peak bone mass is under strong genetic control with estimates of 
heritability ranging from 50% for wrist BMD to 85% for spine and hip BMD in 
various studies (2-4).  Segregation analysis has shown that BMD is a complex 
phenotype that is regulated by interplay between environmental factors and several 
genes each with modest effects on bone mass and bone turnover (2).  Several 
candidate genes have been studied in relation to BMD, include the vitamin D receptor 
(VDR) (5), the oestrogen receptor (6,7), the COLIA1 gene (8), and the TGF-β1 gene 
(9), however, current evidence suggests that allelic variants of these genes accounts 
for only a small portion of the population variance in BMD (10).  Linkage studies in 
man have identified quantitative trait loci on chromosomes 1p36, 2p23-p24, 4q32-34, 
5q33-35, 6p11-12 and 11q12-13 that show probable or definite linkage to BMD in 
families (11-14).  
One of the candidate loci for regulation of BMD in man is on chromosome 1p36.  
This was initially identified by linkage analysis in sib-pairs (11) and it’s candidacy 
was subsequently confirmed by variance components linkage analysis in a separate set 
of families (15).  The tumour necrosis factor receptor superfamily member 1 B 
(TNFRSF1B) is a strong positional and functional candidate gene within this region 
(16).  The TNFRSF1B gene encodes the 75Kd tumour necrosis factor receptor, which 
is highly expressed in osteoclast precursors and plays an important role in mediating 
the effects of TNF on osteoclastogenesis (17).  In a previous study, evidence of an 
allelic association between a specific haplotype of the 3’ untranslated region (UTR) of 
TNFRSF1B and spine BMD was observed but the study population was small and the 
finding has not yet been confirmed in other populations (18).  In order to further 
investigate the candidacy of TNFRSF1B as a genetic determinant of BMD we have 
now examined the relationship between four common polymorphisms of TNFRSF1B 
gene and BMD in a population based sample of 1240 healthy perimenopausal women 
from the UK.  The polymorphisms studied have previously been described in the 
TNFRSF1B gene and were chosen because of their potential effects on receptor 
function.  One is a T to G substitution within exon 6 (T676G) which results in an 
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amino acid substitution (Met→Arg) at codon 196, whereas the other three 
polymorphisms are situated close to each other in the 3’UTR of the mRNA.  Previous 
studies have shown evidence of linkage and association between the T676G coding 
polymorphism and phenotypes relevant to cardiovascular disease such as blood 
pressure and HDL levels (19).  This polymorphism has also been associated with 
rheumatoid arthritis (20) and systemic lupus erythematosus (21).  The 3’UTR 
polymorphisms have been reported to be associated with obesity (22) and Crohn’s 
disease (23). 
 
Results 
The average age of the study subjects was (mean ± SEM) 47.60 ± 0.04 years.  
Approximately 76% of the women were premenopausal and the average time elapsed 
since menopause was 5.01 ± 0.29 years in the postmenopausal group.  159 (12.8%) 
women were taking hormone replacement therapy (HRT) and 102 (8.2%) have had 
hysterectomy. 
Genotype frequencies for the TNFRSF1B polymorphisms were in Hardy-Weinberg 
equilibrium and were as follows: T676G (TT = 50.9%, TG = 42.9%, GG = 6.7%); 
G593A (AG = 48.6%, GG = 28.1%, AA = 23.3%); T598G (TT = 90.3%, GT = 9.7%, 
GG = 0%); T620C (TC = 47.9%, TT = 38.8%, CC = 13.3%).  Allele frequencies for 
these polymorphisms were similar to those previously reported in Caucasians 
(19,24,25).  Linkage disequilibrium (D’) values between the polymorphisms at the 
TNFRSF1B locus are shown in Table 1.  Strong and highly significant linkage 
disequilibrium (LD) was observed between the three polymorphisms located in the 
3’UTR.  The polymorphism T676G located in exon 6 showed LD only with G593A 
and T598G. 
The relationship between genotype and BMD values at the lumbar spine and femoral 
neck adjusted for age, height, weight, menopausal status, and HRT use are shown in 
Table 2.  There was a significant association (p = 0.02) between G593A genotypes 
and femoral neck BMD although this was primarily driven by lower BMD values in 
A/A homozygotes.  Trends for association were also observed with T598G (p = 0.09) 
and T620C (p = 0.05).  There was no significant association between any of the 
polymorphisms and lumbar spine BMD. 
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Since strong linkage disequilibrium was observed between the 3’UTR 
polymorphisms, we investigated the relationship between BMD and genotype groups 
defined by the combination of the three 3’UTR polymorphisms.  The genotypes for 
each polymorphism were coded as 1, 2 or 3 corresponding to homozygote wild type, 
heterozygote or homozygote variant, respectively (i.e. the genotype 121 corresponds 
to 593G/G-598T/G-620T/T).  Thirteen different 3’UTR genotype combination were 
observed in our population and their frequencies are shown in Figure 1.  The 
relationship between 3’UTR genotype combination and femoral neck BMD values, 
adjusted for age, height, weight, menopausal status, and duration of HRT use, are 
shown in Figure 1.  Similar analysis results for lumbar spine were not statistically 
significant (data not shown).  Individuals bearing the genotype 313 (corresponds to 
593A/A-598T/T-620C/C) had significantly lower adjusted femoral neck BMD values 
(least square mean ± SD; 0.843 ± 0.012; n = 85) than those without this genotype 
(0.894 ± 0.003; n = 1155; p = 0.00008).  The results remained statistically significant 
after correction for multiple testing (p = 0.0009).  A similar but non-significant trend 
was observed for lumbar spine BMD (1.044 ± 0.016 vs. 1.065 ± 0.004; p = 0.20). 
The genotype 313 contains two copies of the ATC haplotype.  In view of this, the 
relationship between this haplotype and BMD was investigated.  Individuals with the 
genotypes 322, 222, 221 and 212 were excluded from the analysis because the 
haplotype phase could not be inferred from the DNA sequencing results.  In the 
resulting cohort of 821, subjects were coded according to whether they had 2 copies 
[1,1], one copy [1,0] or no copies [0,0] of the ATC haplotype.  These haplotype 
groups were then investigated in relation to BMD and other variables.  We analysed 
the data using a multiple linear regression model in which the haplotype copy number 
was entered in the regression model, as were other predictors of BMD such as age, 
weight, height, menopausal status, and HRT use.  Results for LS and FN BMD are 
shown in Table 3.  The model shown in Table 3 explained 13.3% and 17.3% of the 
total observed variance in LS and FN BMD, respectively.  Body weight, height and 
years since menopause (YSM) were the most significant independent predictors of LS 
BMD.  The ATC haplotype copy number was not a significant determinant of LS 
BMD but it was the second most significant independent predictor for FN BMD (p = 
0.001) after body weight (p < 0.001).  Height and YSM were also significant 
independent predictors for FN BMD.  However, Body weight accounted for the 
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majority of the total observed variance in LS (~12%) and FN (~15%) BMD.  The 
ATC haplotype accounted for 1.2% of the total observed variance in FN BMD and 
was the second strongest predictor.  Analysis of the relationship between ATC 
haplotype and BMD by general linear model ANOVA showed that adjusted FN BMD 
values were significantly lower in those with two copies of the ATC haplotype (0.843 
± 0.012; n = 85) than those with one copy (0.891 ± 0.009; n= 160) or no copies of the 
ATC haplotype (0.895 ± 0.005; n = 576; p < 0.001) see Figure 2.  Similar results were 
obtained when only premenopausal women were included in the analysis (adjusted 
FN BMD for ATC [1,1] = 0.853 ± 0.014 (n = 66); ATC [1,0] = 0.900 ± 0.010 (n = 
124); ATC [0,0] = 0.896 ± 0.005 (n = 443); p = 0.001).  
 We then extended the haplotype analysis to include the entire population of samples 
(n=1240) by using the programme haplotyper (26) which predicts haplotypes for 
individuals with unknown haplotype phase.  Results were similar to those described 
above (i.e. women with two copies of the ATC haplotype had the lowest adjusted FN 
BMD (0.843 ± 0.012; n= 85) compared to those with one copy (0.892 ± 0.005; n= 
514) or no copies of the ATC haplotype (0.896 ± 0.004; n= 641; p < 0.001)) and no 
other haplotype was significantly associated with BMD.  The T676G polymorphism 
did not give additional information when it was included in the haplotype analysis 
along with the 3’UTR polymorphisms.  The ATC haplotype remained the only 
haplotype significantly associated with FN BMD whether it was associated with the T 
(TATC) or the G allele (GATC) of the T676G polymorphism (data not shown). 
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Discussion 
The cytokine TNF-α has important effects on bone turnover, by modulating 
differentiation and function of cells of the osteoblast and osteoclast lineage (27).  
Studies in vitro have shown that TNF-α can promote osteoclast differentiation 
independent of RANK/RANKL (28) and evidence has been presented to suggest that 
oestrogen deficiency causes bone loss in vivo, by upregulating production of TNF-α 
(29), which, acts through the p55 TNF receptor, encoded by the TNFRSF1A gene, to 
augment osteoclastogenesis (30).  Conversely, TNF induced activation of the p75 
TNF-α receptor, encoded by the TNFRSF1B gene, has been found to suppress 
osteoclastogenesis in vitro (17).  These data indicate that the skeletal response to TNF 
depends on a balance between expression and activation of the TNFRSF1A and 
TNFRSF1B gene products. 
In this study, we investigated the relationship between four polymorphisms in the 
TNFRSF1B gene and BMD in women from Northeast of Scotland.  The T676G is a 
coding polymorphism (196:Met→Arg) located in exon 6 of the gene whereas G593A, 
T598G and T620C are non-coding polymorphisms located close to each other in the 
3’UTR region of the gene.   
No association with the T676G polymorphism and BMD was found but there was a 
strong association between BMD and haplotypes defined by the 3’UTR 
polymorphisms.  This association was highly significant even after correction for 
multiple testing and remained so when confounding factors such as age, weight, 
height, menopausal status, and HRT use were taken into account.  Whilst individual 
polymorphisms in the 3’UTR were only weakly association with BMD, there was a 
strong association between carriage of the A593 –T598 –C620 (ATC) haplotype and 
BMD.  Thus, in both multiple regression and ANOVA analysis, individuals 
homozygous for the ATC haplotype had the lowest FN BMD values compared to 
heterozygotes or those who did not carry the ATC haplotype.  Our previous studies 
(7) along with the data presented here illustrate the importance of haplotype analysis 
in association studies such as these.  Whilst the effect of the ATC haplotype on FN 
BMD was modest (~1.2%), it is of a similar magnitude to other candidate genes which 
have been implicated in the regulation of BMD such as VDR (10,31) and oestrogen 
receptor (7,32).  Furthermore, our study was sufficiently powered to detect such an 
effect.  Based on the 3’UTR genotype frequencies observed in our population, 
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computer simulation showed that our study had 82% and 99% power to detect 
changes in BMD Z-scores (standard deviation unit) of 0.05 and 0.10, respectively. 
These findings are in broad agreement with the work of Spotila et al who also 
reported a positive association between polymorphisms in the 3’UTR of the 
TNFRSF1B gene and BMD in women from the USA (18).  In the Spotila’s study 
however, the association was observed with LS BMD rather than FN BMD and the 
low BMD haplotype was AGT rather that ATC.  Possible explanations for the 
differences between studies include the fact that patients in the Spotila’s study were 
drawn from three different ethnic backgrounds and the fact that the results were based 
on a sample size much smaller than the population studied here.  In this regard, it is of 
interest that the original family based studies by Devoto et al showed evidence of 
linkage to hip BMD rather than spine BMD (11,15), which is in keeping with the 
association with FN BMD which we report here.  The fact that specific candidate 
genes and loci affect BMD differently at different skeletal sites is entirely in keeping 
with evidence from human and animal studies which shows that the effects of genetic 
factors on BMD regulation are site specific (14,33). 
 
Further work will be required to investigate the mechanisms by which the TNFRSF1B 
3’UTR regulate BMD.  Variations in the 3’UTR of genes are known to alter the stem-
loop structure of mRNA and to affect mRNA processing and stability (34-37).  In 
order to assess the possible impact of the 3’UTR polymorphisms on RNA structure, 
we performed computer simulation studies using RNAdraw (38) to study the 
predicted effects of the ATC haplotype on RNA secondary structure.  This showed 
that the presence of the ATC haplotype creates changes in the stem-loop structure 
(compared to the most common haplotype) which potentially could affect mRNA 
processing, translation, or stability (data not shown).  Although these data suggest that 
the ATC haplotype may influence gene function by an effect on mRNA structure, 
functional studies will be required to confirm this.  Another possibility is that the ATC 
haplotype may simply be in linkage disequilibrium with a functional polymorphism 
elsewhere in the TNFRSF1B gene or in a gene nearly.  Neither of these possibilities 
seems likely; the only other known functional polymorphism in TNFRSF1B is the 
T676G coding change and we found no association between this polymorphism and 
BMD.  The nearest functional candidate gene nearby is TNFRSF8, which ends 
approximately 60Kb upstream of TNFRSF1B.  Although this is also a candidate for 
 9 
regulation of BMD and is within the range of expected LD, we have found no 
association between polymorphisms of the TNFRSF8 gene and BMD in the same 
population (Tasker, Albagha & Ralston; unpublished data). 
 
We conclude that, in this relatively large population, allelic variations at the 
TNFRSF1B locus accounts for part of the heritable component of FN BMD, raising 
the possibility that polymorphisms of the TNFRSF1B gene could be useful genetic 
markers for bone mass and susceptibility to osteoporotic fracture.  Further studies in 
other populations will be required to confirm this finding and to determine the 
molecular mechanisms responsible. 
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Subjects and Methods  
 
Subjects 
The study group comprised 1240 women aged 45-54 who were randomly selected from a 
large population based BMD screening programme for osteoporotic fracture risk (39).  The 
screening program involved 7000 women who were selected randomly from the Community 
Health Index records, a database of all patients registered with a general practitioner from a 
25-mile radius of Aberdeen, a city with a population of 500,000 in the North East of Scotland.  
Women were invited by letter to undergo BMD measurements between 1990-1994 and 5119 
of the 7000 invited (73.1%) attended for evaluation.  Participants were weighed on a set of 
balance scales calibrated to 0.05 kg (Seca, Hamburg, Germany) and height was measured 
using a stadiometer (Holtain Ltd, Crymych, United Kingdom).  All participants completed a 
questionnaire on menopausal status, and use of Hormone Replacement Therapy (HRT).  
Information from this questionnaire was combined to identify 5 categories as follows: 1= 
premenopausal, no HRT; 2 = perimenopausal, no HRT; 3 = postmenopausal, no HRT; 4 = 
postmenopausal, previous HRT users; 5 = postmenopausal, current HRT user.  Women were 
classified as premenopausal if they were menstruating regularly, as perimenopausal if 
menstruation was irregular and/or up to 6 months had elapsed since their last period and 
postmenopausal if menstruation had ceased for 6 months or more.  All participants gave 
written informed consent to being included in the study, which was approved by the 
Grampian Research Ethics Committee. 
 
Bone mineral densitometry measurements  
The bone mineral density measurements  (BMD) of the left proximal femur (the femoral neck, 
FN) and lumbar spine, LS (L2-4) were performed by dual energy X-ray absorptiometry using 
a Norland XR26 densitometer (Norland Corp, Wisconsin, USA).  Calibration of the machine 
was performed daily, and quality assurance checked by measuring the manufacturer’s lumbar 
spine phantom at daily intervals and a Hologic spine phantom at weekly intervals.  The in vivo 
precision for the XR26 was 1.95% for the lumbar spine (LS), and 2.31% for the femoral neck 
(FN). 
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Genotyping 
Genomic DNA was extracted from peripheral blood leukocytes.  Genotypes for the 
TNFRSF1B exon 6 polymorphism (T676G; GenBank accession no. M32315) were 
determined by PCR-RFLP analysis as described previously (25).  The G593A, T598G, and 
T620C polymorphisms located in the 3’UTR of the TNFRSF1B gene (GenBank accession no. 
U52165) were detected by direct DNA sequencing.  A 192 bp PCR product containing the 
three polymorphisms was amplified as described previously (18).  PCR products were then 
cleaned using ExoSAP ITTM kit (USB Corporation, Cleveland, Ohio, USA) and sequenced 
using the DYEnamic ET dye terminator cycle sequencing kit (Amersham Pharmacia Biotech 
UK Ltd, Buckinghamshire, UK).  DNA sequencing was performed in 96-well plates which 
were run on a MEGABACE-1000 automated DNA sequencer (Amersham Pharmacia Biotech 
UK Ltd, Buckinghamshire, UK).  To check for genotyping errors, 8 DNA samples were 
randomly selected from each 96-well plate and re-sequenced (n= 104). All genotypes were 
identical to those obtained from the first round of sequencing.  
 
Statistical methods 
Statistical analysis was carried out using Minitab version 12 (Minitab, Inc., Coventry, UK).  
Differences in BMD between the genotypes were tested using a General Linear Model 
analysis of variance (ANOVA) adjusting for age, weight, height, menopausal status, and 
duration of HRT use.  Stepwise multiple linear regression was used to test for independent 
predictors of BMD by entering genotypes, age, weight, height, menopausal status, and 
duration of HRT use into the model.  The Bonferroni correction method was used to correct 
for multiple testing.  Linkage disequilibrium (LD) between the polymorphisms, expressed as 
D’, was analysed using the EH and 2BY2 algorithms (40,41).  Haplotype inference for 
individuals with ambiguous haplotype phase was performed using the Haplotyper programme 
(26). Calculation of the study power was performed using the “Power and sample size” utility 
of the Minitab software 
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 T676G G593A T598G T620C 
T676G -    
G593A 0.286* -   
T598G 0.513* 1.000* -  
T620C 0.077  0.404* 1.000* - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Linkage disequilibrium at the TNFRSF1B locus 
 
 
Values are shown for D’. * Significant at p<0.00001. 
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 Lumbar Spine BMD  p-value Femoral Neck BMD p-value 
 TT (n=611) TG (n=509) GG (n=80) TT (n=611) TG (n=509) GG (n=80) 
T676G* 1.064 + 0.006 1.059 + 0.006 1.078 + 0.016 0.54 0.892 + 0.005 0.886 + 0.005 0.897 + 0.013 0.53 
         
 GG (n=348) GA (n=603) AA (n=289) GG (n=348) GA (n=603) AA (n=289) 
G593A 1.062 + 0.008 1.068 + 0.006 1.056 + 0.009 0.51 0.894 + 0.006 0.896 + 0.005 0.874 + 0.007 0.02 
         
 TT (n=1120) TG (n=120) GG (n=0) TT (n=1120) TG (n=120) GG (n=0) 
T598G 1.062 + 0.004 1.073 + 0.013 NA 0.42 0.889 + 0.003 0.908 + 0.010 NA 0.09 
         
 TT (n=481) TC (n=594) CC (n=165) TT (n=481) TC (n=594) CC (n=165) 
T620C 1.064 + 0.006 1.066 + 0.006 1.052 + 0.011 0.53 0.897 + 0.005 0.891 + 0.005 0.871 + 0.009 0.05 
         
 
 
 
 
 
Table 2. Lumbar spine and femoral neck BMD values in relation to TNFRSF1B genotypes 
 
Values are least square mean + SD BMD values in g/cm2, adjusted for age, weight, height, menopausal status, and HRT use. 
*Data for T676G were available for 1200 subjects. 
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Lumbar Spine BMD  Femoral Neck BMD 
Predictor Coefficient R2  p value  Predictor Coefficient R2  p value 
Weight (kg) 0.0040 0.116 <0.001  Weight (kg) 0.0038 0.153 <0.001 
Height (cm) 0.0036 0.130 <0.001  ATC Haplotype -0.0195 0.165 0.001 
YSM** -0.0036 0.137 0.025  Height (cm)* 0.0019 0.171 0.009 
ATC Haplotype -0.0074 0.138 0.332  YSM** -0.0030 0.178 0.014 
Age (y) -0.0024 0.139 0.496  Age (y) 0.0026 0.179 0.343 
HRT use (yrs) -0.0023 0.139 0.627  HRT use (yrs) -0.0021 0.179 0.563 
Constant 0.3485 -- 0.118  Constant 0.2212 -- 0.202 
 Final Adjusted R2 = 0.133   Final Adjusted R2 = 0.173 
 
 
 
 
 
 
 
 
Table 3. Multiple linear regression analysis of BMD. 
 
*Study subjects were classified into 3 genotype groups: [1,1], [1,0], and [0,0] 
corresponding to individuals with 2 copies, one copy, and subjects without the ATC 
haplotype, respectively. **YSM: years since menopause. 
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Figure 1. TNFRSF1B 3’UTR genotype combinations and FN BMD. *Significantly different 
from 313 genotype (p<0.001). 
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Figure 2. Lumbar Spine (LS) and femoral neck (FN) BMD values in relation to the TNFRSF1B 
3’UTR genotypes defined by the ATC haplotype status. Subjects were coded according to whether 
they had 2 copies [1,1], one copy [1,0] or no copies of the ATC haplotype. 
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